)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Agenus (AGEN) investor relations material
Agenus Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary10 Nov, 2025
Executive summary
Achieved net income of $63.9 million for Q3 2025, reversing a net loss of $66.4 million in Q3 2024, primarily due to a $100.9 million gain from the deconsolidation of MiNK Therapeutics, Inc.
France granted reimbursed compassionate access for BOT/BAL in refractory MSS mCRC, marking the first government-funded access for this population and the first regulatory reimbursement for BOT/BAL.
Two-year survival data for BOT/BAL presented at ESMO and ESMO-GI showed durable, long-term survival in over 400 patients across more than five refractory cancers.
The global Phase 3 BATTMAN trial is set to launch in Q4 2025 across 100+ sites internationally, evaluating BOT/BAL versus best supportive care in refractory, unresectable MSS/pMMR colorectal cancer.
Operating expenses decreased significantly year-over-year, with R&D and G&A expenses down 43% and 37% respectively for the quarter.
Financial highlights
Q3 2025 net income attributable to common stockholders was $63.9 million, or $2.00 per basic share, compared to a net loss of $66.4 million, or $(3.08) per share, in Q3 2024.
Total revenues for Q3 2025 were $30.2 million, up from $25.1 million in Q3 2024, with year-to-date revenue at $80.0 million, up from $76.6 million year-to-date 2024.
Operating loss for Q3 2025 was $4.5 million, with a year-to-date operating loss of $34.6 million, improved from $94.6 million in the prior year.
Cash and cash equivalents at September 30, 2025 were $3.5 million; subsequent to quarter end, $10 million was raised via a promissory note and $4.5 million from at-the-market equity sales.
Debt outstanding was $35.6 million, with $10.5 million due June 2026 and $24.75 million due November 2026.
Outlook and guidance
Management expects current cash, anticipated inflows from Zydus agreements, and projected revenues to cover liquidity needs through 2026, but additional funding will be required for ongoing operations.
Substantial doubt remains about the ability to continue as a going concern for one year after the report date, pending successful completion of further funding transactions.
BATTMAN Phase 3 patient enrollment to begin before year-end 2025.
Neoadjuvant and frontline data updates from investigator-initiated trials expected in the first half of 2026.
France AAC program will generate real-world evidence.
Quantify France AAC revenue impact
BOT/BAL's competitive edge in refractory cancers
Impact of Zydus/MiNK on future cash runway
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Agenus earnings date
Q4 202517 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Agenus Inc. is a biotechnology company focused on the discovery and development of immunotherapies for cancer and other diseases. The company specializes in antibody-based therapies, including immune checkpoint inhibitors and personalized cancer vaccines. Agenus leverages its proprietary research platforms to develop novel treatments that enhance the body's immune response against tumors. Agenus Inc. is headquartered in Lexington, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage